Nanostring Technologies
Nanostring Technologies is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The substudy enrolled 6 participants versus approximately 60 intended, with enrollment in Italy (3 participants), Germany (1), Switzerland (1), and the United States (1).
- All 6 enrolled participants underwent leukapheresis, but only 4 received lymphodepleting chemotherapy and brexucabtagene autoleucel.
These findings describe the trial, not the service provider’s performance or responsibility.
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy D - Relapsed/Refractory Hairy Cell Leukemia (HCL)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
Sponsor iTeos Belgium
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nanostring Technologies?
The 2026-10-09 snapshot links Nanostring Technologies to 6 distinct CTIS trials. Recorded services include Laboratory services, Lab- Tumor Gene Expression testing. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nanostring Technologies?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nanostring Technologies conducted?
The linked trials record locations in 10 countries, including Spain, France, Italy, Austria, Germany. These are trial locations, not confirmed office locations or countries where Nanostring Technologies delivered services.
What can this page tell me about Nanostring Technologies's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nanostring Technologies. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nanostring Technologies Inc.